MFWM
REGN icon

Motley Fool Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Motley Fool Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,485
Closed -$4.24M – 87
2026
Q1 		$4.24M Sell
5,485
-2,307
-30% -$1.77M 0.48% 73
2025
Q4 		$6.01M Sell
7,792
-1,830
-19% -$1.24M 0.47% 76
2025
Q3 		$5.41M Buy
+9,622
New +$5.44M 0.37% 85

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Motley Fool Wealth Management's REGN Position: Q2 2026 in Review

Motley Fool Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 5,485 shares — an estimated $4.24M sold.

Motley Fool Wealth Management first reported a position in REGN in Q3 2025 and held it in 3 quarters. The position peaked at $6.01M in Q4 2025. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Motley Fool Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Motley Fool Wealth Management sold 5,485 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.24M.
  • Motley Fool Wealth Management first reported a position in Regeneron Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Motley Fool Wealth Management's Regeneron Pharmaceuticals position peaked at $6.01M in Q4 2025.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Motley Fool Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.